> Pharmacokinetic  drug interactions  involving  CYP450  are not expected  (see section  5.2).  5  Co-administration  of ICATIBANT ACCORD with angiotensin -converting -enzyme  (ACE)  inhibitors  has not been  studied.  ACE  inhibitors  are contraindicated  in HAE patients  due to possible  enhancement  of bradykinin  levels.  
